Overall survival (OS) analysis revealed that KIFC1 acts as a detrimental factor for patients with ACC, KICH, KIRC, KIRP, LGG, LIHC, LUAD, MESO, PAAD, PCPG, SARC, SKCM, and UCES, while it serves as a protective factor for patients with DLBC and THYM. Here, KIFC1 is linked to thymoma.